Abilify News and Research

RSS
Aripiprazole (marketed as Abilify, Abilify Discmelt) is an atypical antipsychotic medication approved by the Food and Drug Administration (FDA) for the treatment of schizophrenia.
CDR recommends reimbursement for schizophrenia drug, ABILIFY

CDR recommends reimbursement for schizophrenia drug, ABILIFY

Positive topline results from Alkermes ALKS 9070 phase 1b study for schizophrenia

Positive topline results from Alkermes ALKS 9070 phase 1b study for schizophrenia

Bristol-Myers Squibb first quarter net sales increase 5% to $3.3 billion

Bristol-Myers Squibb first quarter net sales increase 5% to $3.3 billion

America’s best loved drugs: Report

America’s best loved drugs: Report

Two surveys show 'huge variation' in health costs in U.S.

Two surveys show 'huge variation' in health costs in U.S.

District Court judgment favors Otsuka in Abilify patent litigation

District Court judgment favors Otsuka in Abilify patent litigation

Quebec recognizes value of ABILIFY for treating schizophrenia and related psychotic disorders

Quebec recognizes value of ABILIFY for treating schizophrenia and related psychotic disorders

Drug companies accused of skirting requirement to submit prices

Drug companies accused of skirting requirement to submit prices

Otsuka opens Canadian operations

Otsuka opens Canadian operations

Bristol-Myers Squibb second-quarter net sales increase 2% to $4.8 billion

Bristol-Myers Squibb second-quarter net sales increase 2% to $4.8 billion

Drug trend for children increased 10.8% in 2009 across America

Drug trend for children increased 10.8% in 2009 across America

Sermo Category Report: About 30% of patients suffer from depression

Sermo Category Report: About 30% of patients suffer from depression

Decrease in manic symptoms severity influences prescribing decisions for bipolar mania

Decrease in manic symptoms severity influences prescribing decisions for bipolar mania

Prescription drug spending up in 2009

Prescription drug spending up in 2009

Bristol-Myers Squibb to review key accomplishments at meeting with investment community

Bristol-Myers Squibb to review key accomplishments at meeting with investment community

Emerging oral atypical antipsychotics to compete in increasingly crowded schizophrenia drug market

Emerging oral atypical antipsychotics to compete in increasingly crowded schizophrenia drug market

Obecure granted patent covering betahistine with olanzapine for mitigating antipsychotic drug associated weight gain

Obecure granted patent covering betahistine with olanzapine for mitigating antipsychotic drug associated weight gain

Obecure enters into licensing and clinical supply agreement with Grunenthal's subsidiary for XR betahistine

Obecure enters into licensing and clinical supply agreement with Grunenthal's subsidiary for XR betahistine

Alkermes develops proprietary LinkeRx technology platform to create injectable antipsychotics

Alkermes develops proprietary LinkeRx technology platform to create injectable antipsychotics

Generic erosion to decrease branded atypical antipsychotics schizophrenia drug market to $5.2B

Generic erosion to decrease branded atypical antipsychotics schizophrenia drug market to $5.2B